The United Kingdom and the United States have forged a significant commercial pact that will keep no levies on British medicine exports entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to raise spending on pharmaceuticals through the National Health Service (NHS). This move guarantees that tariffs on these crucial goods will remain at zero for a period of the next three years.
This development comes after recent threats to dramatically increase duties on patented pharmaceutical imports, with figures mentioned up to double the cost.
"This agreement with the Britain reinforces the global environment for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," an announcement noted.
Trade Significance
Drugs are one of the the United Kingdom's biggest export categories to the America, which is easily the biggest destination for leading British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of September, the UK shipped medicines totaling £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that period.
"This agreement protects jobs, boosts capital expenditure and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall health service expenditure on treatments from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates were more than twenty percent.
Recent Tensions
The pact takes place against a long-running row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
These tensions were intensified by assertions that US patients were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been announced toward US facilities.
The Science Minister stated that the NHS must spend more on treatments, noting that its budget allocation on drugs had declined as a share of its overall budget over the past decade.
